Drugs and patents in ATC class N06D

Last updated: July 26, 2026

Anti-dementia care (ATC N06D) is built around five active ingredient “pillars”: acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA antagonist (memantine), plus combination therapy (memantine + donepezil). Patent exposure is fragmented by molecule-specific composition-of-matter, salt/polymorph, formulation, and method-of-use coverage, with regulatory exclusivities and follow-on patents shaping generic timing and competitive entry. Generic competition is already active across multiple markets for donepezil, rivastigmine, galantamine, and memantine. The remaining patent barriers are mainly formulation and delivery-system claims (notably rivastigmine and other long-acting products) and line-extension method-of-use claims where they exist. In the combination segment, the market is smaller but the patent estate tends to be more concentrated around combination composition and dosing/regimen claims, which can delay generic entry longer than single-entity products.

Which patents protect anti-dementia drugs in ATC N06D (donepezil rivastigmine galantamine memantine) and what do they cover?

The N06D portfolio typically splits into four IP layers:

Composition of matter for the active ingredient (and sometimes specific salts and stereochemical forms).
Pharmaceutical formulation patents (immediate-release vs controlled/extended-release; transdermal systems; film-coated tablets; oral liquids).
Delivery-system and manufacturing method patents (notably patches and depot-style platforms).
Method-of-use patents (dose regimens, titration schedules, combination dosing, and therapeutic use or patient subgroups).

Donepezil (ATC N06DA02): what patent types still matter after composition expiration?

For donepezil, the original composition-of-matter estates in major jurisdictions have largely passed or are near passing. Competitive differentiation in later years tends to come from:

Formulation improvements (fasted/fed bioavailability targeting; orally disintegrating or modified-release formats).
Salt specifications and polymorphs, where claimed.
Method-of-use claims (specific dosing steps and titration).
Packaging/handling and manufacturing processes, where they are separately claimed.

Rivastigmine (ATC N06DA03): why delivery-system patents matter most

Rivastigmine is the clearest case for delivery-system patent persistence because of its transdermal route (patch). Coverage can include:

Patch backing, adhesive matrix composition, drug concentration, and release-rate control.
Manufacturing method steps for controlling adhesion and drug permeation.
Formulation patents for oral capsules and solution (extended stability, specific excipient blends).
Potential polymorph or salt claims depending on jurisdiction and whether new crystal forms were disclosed.

Galantamine (ATC N06DA04): formulation and method-of-use as key battlegrounds

Galantamine markets include immediate-release tablets and extended-release formulations. Patent leverage tends to shift toward:

Modified-release formulation claims (matrix and coating systems).
Method-of-use claims (dose escalation, tolerability-driven regimens).
Specific excipient systems and solid-state form constraints.

Memantine (ATC N06DX01) and how patents evolve from active ingredient to extended release

Memantine has immediate-release and extended-release formulations in some geographies. Where composition is expired, follow-on value concentrates in:

Extended-release formulation patents (release kinetics).
Specific polymorphs or solid-state forms if claimed.
Manufacturing controls tied to dissolution profile.

Memantine + donepezil (combination therapy): what tends to be protected

Combination products generally add a layer:

Composition claims covering the combination and dosing ratios.
Regimen and method-of-use claims tied to initiating or maintaining combination therapy.
Formulation claims (fixed-dose combinations, unit dose design, dissolution characteristics).

When does each ATC N06D anti-dementia drug lose exclusivity in key markets (US EU UK) and what drives the clock?

“Exclusivity” in anti-dementia is governed by a mix of:

Patent term (filing date-based; extended where eligible).
Regulatory exclusivities (US: NCE exclusivity for new active ingredients, and 5-year/3-year exclusivity rules for new clinical investigations for certain approvals).
Market authorization reference product status and data exclusivity under EU mechanisms.
Continued patent term for transdermal and extended-release lines.

Practical timing pattern across N06D

Early exclusivity: mostly finished for donepezil, rivastigmine, galantamine, memantine in many countries due to time since first approval.
Later exclusivity: can persist via formulation and delivery-system patents, most notably rivastigmine patches and specific modified-release dosage forms.
Combination lag: fixed-dose combinations can have later-filed patents that extend beyond single-entity expiration.

What is the Orange Book status for anti-dementia drugs (donepezil rivastigmine galantamine memantine, combinations), and which patents are listed?

In the US, the Orange Book organizes approved drug products by active ingredient strength and lists patents submitted under relevant statutes (21 USC 355(b)(1) and related provisions). For anti-dementia products, the key question for generic planning is which listed patents are relevant to the generic’s proposed label and formulation.

Featured-snippet answer:

Orange Book status for N06D typically includes multiple patent families per marketed strength, often partitioned into formulation and method-of-use listings once composition-of-matter patents expire.

Patent listing categories that drive Paragraph IV risk

“Drug substance” patents for active ingredient: usually expire earlier (given age of initial invention).
“Drug product” patents: often include modified-release, film coatings, patch designs, and excipient/procedure-related claims.
“Use” patents: tend to include dosage regimens or therapeutic uses for specific cognitive disorder subtypes.

How many patents cover long-acting and transdermal rivastigmine and what formulation claims block generics?

Rivastigmine is the dominant case for delivery-system claim density in N06D. Generic risk is often highest when:

The generic targets the same transdermal delivery system performance requirements.
The Orange Book lists “drug product” patents for the patch.
Method-of-use patents are listed alongside the drug product patents.

Typical claim scope that blocks entry

Adhesive matrix composition enabling a specific permeation rate.
Controlled release profile driven by polymer/solvent system.
Patch architecture (matrix thickness, backing, micro-porous structures).
Manufacturing method and quality attributes (drug dispersion uniformity).

Litigation pattern

Where delivery-system patents are present, disputes tend to cluster around:

Non-infringement arguments (different release mechanism or formulation).
Invalidity (lack of novelty/obviousness; enablement or written description issues).
Settlement agreements after Paragraph IV filings.

Which companies are challenging anti-dementia patents with Paragraph IV and what settlement dynamics exist?

Generic entrants in N06D generally prioritize:

Strengths/dosage forms with fewer enforceable “drug product” patents.
Products where litigation history has already clarified infringement/validity outcomes.
Use of licensing or “authorized generic” pathways after settlements.

Competitive behavior by segment

Donepezil: entry often focuses on immediate-release generics; fewer delivery-system barriers than rivastigmine.
Rivastigmine: patch-focused filings face the highest formulation patent scrutiny; patch performance can be a gating variable.
Galantamine: extended-release vs immediate-release drives the litigation profile.
Memantine: extended-release can present distinct drug product patents.
Combinations: fewer entrants, more likely to hinge on combination composition and dosing regimen claims.

(If the request is company-specific and settlement-specific down to docket numbers, that requires the product-level Orange Book patent listing and the Paragraph IV case docket history, which is not provided here.)

What generic entry risks exist for anti-dementia drugs: non-infringement, invalidity, and supply strategy

Entry risks in N06D can be modeled as three gating questions:

Is the proposed generic within the claim scope?
- For formulation patents: assess drug release profile and manufacturing differences.
- For method-of-use: assess label wording and off-label promotion risk.
Do the relevant listed patents remain in force as of the planned launch?
- If patents expire late in the launch window, Paragraph IV leverage can collapse into “hold” periods.
Is there an injunction or delayed approval trigger?
- A successful infringement finding (or settlement terms) can delay launch even if patent validity arguments exist.

Supply strategy implications

Companies often stage rollout by NDC strength.
When patch delivery-system patents dominate, entrants may wait for patent cliffs or pursue alternative delivery routes not covered by the core claims.

How do anti-dementia patent estates compare: donepezil vs rivastigmine vs galantamine vs memantine vs memantine-donepezil?

Patent architecture by molecule:

Donepezil: usually composition is dominant historically; now the practical bottleneck is fewer later delivery-specific patents, so generic dynamics are more tolerant than rivastigmine.
Rivastigmine: delivery-system (transdermal) patents create a more complex estate that extends competitive differentiation and drives longer “effective exclusivity” even after initial substance expiration.
Galantamine: modified-release formulations can create specific “drug product” obstacles.
Memantine: similar to galantamine for extended-release; generally less complex than transdermal patch ecosystems.
Memantine + donepezil: combination-specific patents and regimen claims can concentrate risk and reduce the number of viable generic routes.

What FDA regulatory status and approval pathways affect patent challenges for N06D drugs?

FDA pathway decisions tie directly into timing:

ANDA pathway (generics) drives Paragraph IV risk where listed patents exist.
505(b)(2) pathways can be used for line extensions, potentially altering which patents are relevant by changing route/formulation or claim coverage.

Key label-driven mechanics:

If the generic’s intended use matches a “use” patent’s claim scope, label positioning becomes central.
If the formulation differs materially, “drug product” patent infringement questions become central.

What formulations are protected in anti-dementia drugs: patches, extended-release tablets, orally disintegrating forms?

Rivastigmine patch (transdermal)

Protected formulations typically include the drug-in-adhesive system, polymer matrix controls, and release kinetics.

Donepezil modified release and special oral formats

When present, patents cover specific modified release and film coating or excipient systems tied to dissolution and bioavailability.

Galantamine and memantine extended release

Coverage often concentrates around release-control matrices and coating systems that generate distinct dissolution profiles.

Fixed-dose combinations

Protected forms include fixed-ratio units and dosing regimens embedded in the approved label context.

What patent litigation affects anti-dementia drugs and how does it shape launches (injunctions vs settlements)?

The typical N06D litigation progression:

ANDA Paragraph IV filing triggers a 30-month stay in most scenarios where at least one patent is asserted.
Parties negotiate settlements that can include:
- Launch date covenants (designated “at-risk” launch windows).
- Agreed non-infringement positions or engineered design-arounds.
- Authorized generic licenses to capture market share while avoiding full trial.

The commercial effect:

Even where generic approval is obtained, patent-driven stays and settlement terms determine effective market entry dates.

Which ATC N06D drugs face the highest remaining patent barriers and where are the biggest revenue exposures?

Highest remaining barriers in practice are concentrated in:

Transdermal delivery systems (rivastigmine patch markets).
Extended-release formulations with distinct “drug product” patent listings.
Combination products with clustered combination and dosing regimen claims.

Revenue exposure remains greatest where:

The molecule is still broadly prescribed under branded and generic competition with limited delivery-route alternatives.
Formulation patents constrain interchangeable generic switching (patch replacement is a slower market process than simple tablet substitution).

Key Takeaways

N06D’s patent landscape is mostly post-composition estates, led by formulation, delivery systems, and method-of-use claims.
Rivastigmine’s transdermal system creates the most persistent “effective exclusivity” and the highest generic entry friction.
Donepezil, galantamine, and memantine generics are generally less constrained by delivery-system barriers, though extended-release and line-extension formulations can still carry meaningful drug product patent lists.
Combination therapy tends to concentrate patent risk around fixed-dose composition and regimen claims, shaping fewer, slower generic entry routes.
FDA approval pathway mechanics (ANDA vs 505(b)(2)) and Orange Book “listed patents” determine Paragraph IV leverage and launch timing.

FAQs

How do Orange Book “drug product” patents differ from “use” patents for anti-dementia ANDA filings?
Do rivastigmine patch generics need to match release kinetics to avoid drug product patent infringement?
What label design changes can reduce method-of-use patent exposure for anti-dementia generics?
How do 30-month stays typically affect real-world generic launch timing in N06D?
Which anti-dementia fixed-dose combinations have the most concentrated patent estates and why?

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-26).
World Health Organization. ATC Classification System: N06D Anti-dementia drugs. https://www.whocc.no/atc_ddd_index/ (accessed 2026-07-26).

Drugs in ATC Class N06D

Subclasses in ATC: N06D - ANTI-DEMENTIA DRUGS

Market dynamics and patent landscape for ATC Class N06D (anti-dementia drugs): what protects donepezil, rivastigmine, galantamine, memantine, and combinations, and when generics can launch